The combination of cisplatin and D-penicillamine has been demonstrated to enhance the anti-tumor effects of oxaliplatin in oxaliplatin-resistant S3 xenograft tumors, particularly in cases with downregulated hCtr1 expression and overexpressed ATP7A (Koraishy et al., 2013). Here, SLC31A1 is linked to neoplasm.